Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-01-16
2007-01-16
Chan, Christina (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S069100, C436S008000, C436S015000, C424S184100, C530S324000
Reexamination Certificate
active
11090353
ABSTRACT:
The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolypmers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 3991210 (1976-11-01), Shea
patent: 4129666 (1978-12-01), Wizerkaniuk
patent: 4339431 (1982-07-01), Gaffar
patent: 5204099 (1993-04-01), Barbier et al.
patent: 5554372 (1996-09-01), Hunter et al.
patent: 5583031 (1996-12-01), Stern
patent: 5591629 (1997-01-01), Rodriguez et al.
patent: 5623052 (1997-04-01), McLean et al.
patent: 5627206 (1997-05-01), Hupe et al.
patent: 5668117 (1997-09-01), Shapiro et al.
patent: 5719296 (1998-02-01), Acton, III et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5886156 (1999-03-01), McLean et al.
patent: 5958972 (1999-09-01), Hupe et al.
patent: 5965600 (1999-10-01), Sato et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6024981 (2000-02-01), Khankari et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6162800 (2000-12-01), Dolle et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Konfino et al.
patent: 6514938 (2003-02-01), Gad et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6800285 (2004-10-01), Rodriguez et al.
patent: 6800287 (2004-10-01), Gad et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz et al.
patent: 6939539 (2005-09-01), Konfino et al.
patent: 2001/0055568 (2001-12-01), Gilbert et al.
patent: 2002/0037848 (2002-03-01), Eisenbach-Schwartz et al.
patent: 2002/0107388 (2002-08-01), Vandenbark
patent: 2002/0115103 (2002-08-01), Gad et al.
patent: 2003/0004099 (2003-01-01), Eisenbach-Schwartz et al.
patent: 2003/0170729 (2003-09-01), Klinger
patent: 2004/0006022 (2004-01-01), Strominger et al.
patent: 2004/0106554 (2004-06-01), Konfino et al.
patent: 2005/0014694 (2005-01-01), Yong et al.
patent: 2005/0019322 (2005-01-01), Rodriguez et al.
patent: 2005/0038233 (2005-02-01), Gad et al.
patent: 2005/0170004 (2005-08-01), Rosenbeger et al.
patent: 2005/0171286 (2005-08-01), Konfino et al.
patent: 2005/0256046 (2005-11-01), Gad et al.
patent: DE 3930733 (1991-03-01), None
patent: 0378246 (1986-06-01), None
patent: 0383620 (1990-08-01), None
patent: WO 9202543 (1992-02-01), None
patent: 0359783 (1995-11-01), None
patent: WO 9533475 (1995-12-01), None
patent: 1292279 (2003-03-01), None
patent: 1690368 (1995-08-01), None
patent: 1469826 (1995-11-01), None
patent: 1182051 (1985-09-01), None
patent: 1664845 (1991-07-01), None
patent: WO 8802139 (1988-12-01), None
patent: WO 9403484 (1994-02-01), None
patent: WO 9426774 (1994-11-01), None
patent: WO 9526980 (1995-10-01), None
patent: WO 9531990 (1995-11-01), None
patent: WO 9531997 (1995-11-01), None
patent: WO 9830227 (1998-07-01), None
patent: WO 0005249 (2000-02-01), None
patent: WO 0005250 (2000-02-01), None
patent: WO 0018794 (2000-04-01), None
patent: WO 0020010 (2000-04-01), None
patent: WO 0027417 (2000-05-01), None
patent: WO 0152878 (2001-07-01), None
patent: WO 0160392 (2001-08-01), None
patent: WO 0193828 (2001-12-01), None
patent: WO 0193893 (2001-12-01), None
patent: WO 0197846 (2001-12-01), None
Pharmacia Biotech Directory, 1996, pp. 340-341.
Sela, M., et al., “Synthetic Approaches to Vaccines for Infectious and Autoimmune Diseases” Vaccine, 1992, vol. 10, Issue 14, 991-999.
Abramsky, et al., “Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis”,J. Neurol. Sci., 1977, 31, 433-438.
Aharoni, et al., “T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis”,Eur. J. Immunol., 1993, 23, 17-25.
Aharoni, et al., “Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease”,Immunol. Letters, 1997, 58, 79-87.
Alvord, et al., “Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys”,Ann. Neurol., 1979, 6, 469-473.
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen”,Israel J. Med. Sci., 1972, 8, 1759-1760.
Arnon, et al., “Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids”,Neurol., 1978, 28, 336 (Abstract).
Arnon, et al., “Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues” inThe Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis(Academic Press, New York, 1980) 105-107.
Arnon, “A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy” inProgress in Multiple Sclerosis Research(Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418.
Arnon, “Experimental Allergic Encephalomyelitis—Susceptibility and Suppression”,Immunological Rev., 1981, 55, 5-30.
Arnon, et al., “Suppression of Demyelinating Diseases by Synthetic Copolymers”, inA Multidisciplinary Approach to Myelin Disease(G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250.
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by Cop-1—Relevance to Multiple Sclerosis”,Israel J. Med. Sci., 1989, 25, 686-689.
Arnon, et al., “Immunomodulation of Experimental Allergic Encephalomyelitis”,Israel J. Med. Sci., 1993, 29, 175-181.
Arnon, et al., “On the Existence of Suppressor Cells”,Int. Arch. Allergy Immunol., 1993, 100, 2-7.
Arnon, et al., “Immunospecific Drug Design—Prospects for Treatment of Autoimmune Disease”,Therapeutic Immunol., 1994, 1, 65-70.
U.S. Appl. No. 09/359,099, filed Jul. 22, 1999, Strominger, et al.
U.S. Appl. No. 09/487,793, filed Jan. 20, 2000.
U.S. Appl. No. 09/620,216, filed Jul. 20, 2002.
U.S. Appl. No. 09/765,301.
Babu et al., “Reevaluation of response patterns of nonresponder mice to GLPhe polymers”,Immunogen., 1983, 18(1): 97-100 (Abstract).
Babu et al., “Ir gene control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer”,J. Immunogenet., 1984, 11(3-4): 251-254.
Bansil, et al., “Multiple Sclerosis: Pathogenesis and Treatment”,Seminars in Neurol., Jun. 1994, 14(2), 146-153.
Baumhefner, et al., “Copolymer 1 as Therapy for Multiple Sclerosis: The Cons”,Neurol., 1988, 38(Suppl. 2), 69-71.
Baxevanis et al., “Genetic Control of T-Cell Proliferative Responses to Poly (Glu40Ala60) and Poly (Glu51Lys34Tyr15): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies”,Immunogenetics, 1980, 11: 617-628.
U.S. Appl. No. 09/765,644.
U.S. Appl. No. 09/875,429, filed Jun. 5, 2001, Yong and Chabot.
U.S. Appl. No. 09/885,227, filed Jun. 5, 2001, Rodriguez and Ure.
Ben-Nun, et al., “The Autoimmune Reactivity to Myelin Oligodendrocyte Glycoprotein (MOG)in Multiple Sclerosis is Potentially Pathogenic: Effect of Copolymer 1 on MOG-induced Disease”,J. Neurol., 1996, 243(Suppl. 1). S14-S22.
Bornstein, et al., “Trea
Gad Alexander
Lis Dora
Chan Christina
Cooper & Dunham LLP
Huynh Phuong
White, Esq. John P.
Yeda Research and Development Co. Ltd.
LandOfFree
Copolymer 1 related polypeptides for use as molecular weight... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Copolymer 1 related polypeptides for use as molecular weight..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Copolymer 1 related polypeptides for use as molecular weight... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3759787